These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 38964919)
1. [The impact of donor human leukocyte antigen-Bw4 allele on natural killer cell reconstitution and transplant-related mortality in haploidentical transplantation]. Zhao M; Xu ZL; Yu XX; Ding YY; Chang YJ; Zhang XH; Liu KY; Huang XJ; Zhao XY Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):453-461. PubMed ID: 38964919 [No Abstract] [Full Text] [Related]
2. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944 [TBL] [Abstract][Full Text] [Related]
3. [Impact of donor KIR2DS5 genotype on outcome following haploidentical hematopoietic stem cell transplantation]. Wang H; He Y; Wang HH; Wang M; Zhai WJ; Zhou Z; Zhang RL; Zhai WH; Feng SZ; Han MZ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):111-5. PubMed ID: 18315912 [TBL] [Abstract][Full Text] [Related]
4. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Foley BA; De Santis D; Van Beelen E; Lathbury LJ; Christiansen FT; Witt CS Blood; 2008 Jul; 112(2):435-43. PubMed ID: 18385451 [TBL] [Abstract][Full Text] [Related]
5. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor? Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900 [TBL] [Abstract][Full Text] [Related]
6. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417 [TBL] [Abstract][Full Text] [Related]
7. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361 [TBL] [Abstract][Full Text] [Related]
8. A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors. Nakamae H; Fujii K; Nanno S; Okamura H; Nakane T; Koh H; Nakashima Y; Nakamae M; Hirose A; Teshima T; Hino M Transpl Int; 2019 Dec; 32(12):1322-1332. PubMed ID: 31432532 [TBL] [Abstract][Full Text] [Related]
9. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. Willem C; Makanga DR; Guillaume T; Maniangou B; Legrand N; Gagne K; Peterlin P; Garnier A; Béné MC; Cesbron A; Le Bourgeois A; Chevallier P; Retière C J Immunol; 2019 Apr; 202(7):2141-2152. PubMed ID: 30787107 [TBL] [Abstract][Full Text] [Related]
11. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278 [TBL] [Abstract][Full Text] [Related]
13. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation. Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C; Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295 [TBL] [Abstract][Full Text] [Related]
14. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bashey A; Solomon SR Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530 [TBL] [Abstract][Full Text] [Related]
15. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT. Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702 [TBL] [Abstract][Full Text] [Related]
16. HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients. Zhao XY; Chang YJ; Xu LP; Zhang XH; Liu KY; Li D; Huang XJ Br J Cancer; 2014 Sep; 111(6):1080-8. PubMed ID: 25077441 [TBL] [Abstract][Full Text] [Related]